GLP-1 Drugs Beyond Diabetes & Obesity: Approved Uses, Emerging Evidence & Clinical Guide (2026)

GLP-1 Drugs Beyond Diabetes and Obesity: A Clinician's Guide to What's Proven and What's Still Promising

GLP-1 receptor agonists have rapidly evolved from being diabetes medications to multi-system therapies with proven benefits across cardiovascular, renal, hepatic, and metabolic diseases. However, the growing excitement around these drugs has also created confusion, with many emerging indications still lacking robust clinical evidence.

For physicians, endocrinologists, cardiologists, and primary care clinicians, distinguishing between approved uses and promising research is essential. This guide categorizes current evidence into three practical tiers: approved indications, emerging evidence, and experimental applications.

Why Have GLP-1 Drugs Expanded Beyond Diabetes?

GLP-1 receptor agonists were initially developed to improve glycaemic control in type 2 diabetes. Their widespread receptor distribution throughout the body explains why their therapeutic benefits extend well beyond blood glucose management.

GLP-1 Receptors Are Found In:

• Pancreas
• Brain
• Heart
• Kidneys
• Liver
• Blood vessels
• Gastrointestinal tract

How They Work

Besides stimulating insulin secretion and reducing glucagon release, GLP-1 receptor agonists:

• Promote satiety
• Slow gastric emptying
• Reduce body weight
• Improve endothelial function
• Reduce systemic inflammation
• Influence reward pathways involved in addiction

Tirzepatide further enhances these effects by activating both GLP-1 and GIP receptors.

Tier 1: Approved Indications Supported by Large Clinical Trials

These indications have received regulatory approval and are supported by dedicated outcome trials.

Cardiovascular Risk Reduction

Several GLP-1 receptor agonists—including semaglutide, oral semaglutide, liraglutide, and dulaglutide—reduce major adverse cardiovascular events in patients with type 2 diabetes at elevated cardiovascular risk.

Clinical trials consistently demonstrate approximately a 20% reduction in major cardiovascular events, including heart attack, stroke, and cardiovascular death.

Key Evidence

• SOUL Trial
• LEADER Trial
• REWIND Trial
• SUSTAIN Program

Chronic Weight Management

Semaglutide, liraglutide, and tirzepatide are approved for chronic weight management in adults with obesity or overweight accompanied by weight-related comorbidities.

The OASIS-4 trial also demonstrated that oral semaglutide achieved substantial weight reduction in adults without diabetes.

Cardiovascular Risk Reduction in Obesity Without Diabetes

Semaglutide has expanded beyond weight loss to reduce cardiovascular risk in adults with obesity or overweight and established cardiovascular disease—even without diabetes.

This represents one of the most significant label expansions for the GLP-1 class.

Chronic Kidney Disease (CKD)

Injectable semaglutide is now approved for slowing kidney disease progression in patients with type 2 diabetes and CKD.

Benefits include:

• Slower decline in kidney function
• Reduced risk of kidney failure
• Lower cardiovascular mortality

Landmark Trial

• FLOW Trial

Obstructive Sleep Apnea (OSA)

Tirzepatide has become the first GLP-1/GIP agonist approved for treating moderate-to-severe obstructive sleep apnea in adults with obesity.

Supporting Evidence

• SURMOUNT-OSA Trial

Weight reduction significantly decreases upper airway fat deposition, improving airway patency during sleep.

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Semaglutide is now approved for MASH, the inflammatory stage of metabolic fatty liver disease.

ESSENCE Trial Highlights

Semaglutide demonstrated:

• Resolution of steatohepatitis
• Improvement in liver fibrosis
• Better overall liver histology compared with placebo

This approval is particularly relevant for India, where obesity, diabetes, and fatty liver disease continue to rise rapidly.

Heart Failure with Preserved Ejection Fraction (HFpEF)

Although not universally listed as an independent indication, semaglutide and tirzepatide have shown meaningful improvements in:

• Exercise capacity
• Quality of life
• Heart failure symptoms

Major Trials

• STEP-HFpEF
• STEP-HFpEF-DM
• SUMMIT Trial

Tier 2: Strong Clinical Signals, But Evidence Is Still Evolving

These indications have encouraging randomized studies but remain off-label or under regulatory review.

Alcohol Use Disorder (AUD)

Among all emerging indications, alcohol use disorder has generated some of the strongest clinical interest.

Randomized placebo-controlled trials suggest semaglutide reduces alcohol cravings and drinking frequency, likely through modulation of dopamine-mediated reward pathways rather than appetite suppression alone.

Observational analyses have also suggested tirzepatide may produce even greater reductions in alcohol consumption.

Current Limitations

• No head-to-head comparisons with naltrexone
• No long-term outcome trials
• Not currently recommended as first-line therapy

Polycystic Ovary Syndrome (PCOS)

GLP-1 receptor agonists improve:

• Weight loss
• Insulin resistance
• Ovulatory function

Although promising, their use in PCOS remains off-label, and current evidence comes primarily from smaller clinical studies.

Given India's high prevalence of PCOS, this remains an important area of ongoing research.

Autoimmune and Inflammatory Diseases

Several Phase 3 studies are evaluating tirzepatide in combination with biologic therapies for:

Under Investigation

• Plaque psoriasis
• Psoriatic arthritis
• Ulcerative colitis
• Crohn's disease

At present, these therapies should be viewed as investigational rather than clinically established.

Tier 3: Biologically Plausible but Not Yet Clinically Proven

Several exciting hypotheses have emerged, but current evidence does not support routine clinical use.

Alzheimer's Disease: The Biggest Reality Check

GLP-1 drugs initially appeared highly promising for Alzheimer's disease.

Large observational studies suggested patients receiving semaglutide experienced substantially lower rates of Alzheimer's diagnosis compared with other diabetes therapies.

However, the Phase 3 EVOKE and EVOKE+ trials told a different story.

Despite improvements in inflammatory biomarkers, semaglutide failed to slow cognitive decline in patients with early Alzheimer's disease.

Clinical Takeaway

Observational associations—even involving millions of patients—do not replace randomized controlled trials.

At present, GLP-1 receptor agonists should not be prescribed for cognitive protection.

Other Substance Use Disorders

Early research continues in:

• Nicotine dependence
• Opioid use disorder
• Cocaine addiction

Current evidence remains preliminary and insufficient for routine clinical practice.

Osteoarthritis and Joint Pain

Many patients report reduced joint pain while receiving GLP-1 therapy.

Current evidence suggests this improvement is primarily due to:

• Significant weight loss
• Reduced mechanical stress on joints

A direct disease-modifying effect has not been established.

Anti-Ageing and Brain Health Claims

Social media has popularized GLP-1 drugs as "anti-ageing" therapies.

There is currently no high-quality clinical evidence supporting claims of:

• Slowed ageing
• Enhanced longevity
• Prevention of cognitive decline
• General neuroprotection

The negative Alzheimer's trials provide an important reminder that biological plausibility does not necessarily translate into meaningful clinical benefit.

Practical Clinical Considerations for Indian Physicians

Match the Drug to the Approved Indication

Patients may simultaneously qualify for GLP-1 therapy because of diabetes, obesity, cardiovascular disease, CKD, or MASH.

Clearly document the primary treatment indication, as this influences:

• Follow-up
• Monitoring
• Insurance reimbursement
• Government health scheme eligibility

Consider Long-Term Affordability

In India, medication cost remains one of the biggest barriers to sustained treatment.

When affordability is limited, prioritizing indications with demonstrated reductions in mortality and major cardiovascular or renal outcomes is generally more appropriate than prescribing solely for weight reduction.

Set Realistic Patient Expectations

Patients increasingly ask whether GLP-1 medications can improve:

• Fatty liver disease
• Sleep apnea
• Memory
• Alcohol dependence
• Arthritis
• Ageing

Clinicians should clearly distinguish between:

Evidence-Based Benefits

• Diabetes
• Obesity
• Cardiovascular disease
• CKD
• MASH
• Obstructive sleep apnea

Emerging or Experimental Uses

• Alcohol use disorder
• PCOS
• Autoimmune diseases
• Alzheimer's disease
• Other addictions

Maintaining this distinction helps avoid both overpromising and underutilizing an important therapeutic class.

Counsel Patients About Adverse Effects

Regardless of indication, clinicians should discuss common and serious adverse effects.

Common Adverse Effects

• Nausea
• Vomiting
• Diarrhoea
• Constipation

Rare but Important Risks

• Acute pancreatitis
• Gallbladder disease
• Gastrointestinal intolerance

Regular monitoring and patient education remain essential for safe long-term therapy.

Key Takeaways

GLP-1 receptor agonists have evolved into one of the most versatile therapeutic classes in modern medicine. Strong evidence now supports their use in cardiovascular disease, obesity, chronic kidney disease, MASH, and obstructive sleep apnea. Meanwhile, promising research in alcohol use disorder, PCOS, and inflammatory diseases continues to expand their potential.

However, clinicians should remain cautious about indications such as Alzheimer's disease, anti-ageing, and other experimental uses, where encouraging biological hypotheses have yet to translate into proven clinical benefit. Separating established evidence from emerging science remains the cornerstone of evidence-based prescribing.

#GLP1Therapy #ClinicalMedicine